AMAG Pharmaceuticals, Inc. (AMAG) Release: Study Showing Effectiveness Of Mugard® For Management Of Oral Mucositis Featured In The Journal Cancer
4/28/2014 9:08:54 AM
WALTHAM, Mass., April 28, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available today. MuGard is a mucoadhesive hydrogel that forms a protective coating over the oral mucosa. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing the mouth and throat soreness associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by